Understanding how certain proteins contribute to aggressive breast cancer
SRC-3/PELP1 complexes drive stem-like phenotypes in luminal breast cancer
['FUNDING_R01'] · UNIVERSITY OF MINNESOTA · NIH-10737629
This study is looking at how certain proteins help aggressive breast cancer cells, especially the ones that don't respond to regular treatments, to survive and grow, with the hope of finding new ways to better target these tough cells and improve treatment options for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MINNESOTA (nih funded) |
| Locations | 1 site (MINNEAPOLIS, UNITED STATES) |
| Trial ID | NIH-10737629 on ClinicalTrials.gov |
What this research studies
This research investigates the role of specific protein complexes in the development of aggressive breast cancer, particularly focusing on breast cancer stem-like cells (BCSCs) that resist standard treatments. The team aims to identify the signaling pathways that allow these cells to thrive and evade therapies, which could lead to new strategies for targeting them. By studying the interactions between proteins like PELP1 and SRC-3, the researchers hope to uncover mechanisms that drive cancer recurrence and resistance. This work involves both laboratory experiments and advanced techniques to analyze cellular behavior in breast cancer models.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced breast cancer, particularly those who have shown resistance to standard endocrine therapies.
Not a fit: Patients with early-stage breast cancer or those who do not have hormone receptor-positive tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target therapy-resistant breast cancer cells, improving outcomes for patients.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in breast cancer, indicating that this approach could yield significant advancements.
Where this research is happening
MINNEAPOLIS, UNITED STATES
- UNIVERSITY OF MINNESOTA — MINNEAPOLIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LANGE, CAROL A — UNIVERSITY OF MINNESOTA
- Study coordinator: LANGE, CAROL A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Mammary Cancer, Breast Cancer Model, mammary cancer model, Breast Cancer Treatment, Breast Cancer Cell